Landos Biopharma Inc (LABP)
22.46
+0.16
(+0.72%)
USD |
NASDAQ |
May 17, 16:00
22.46
0.00 (0.00%)
After-Hours: 20:00
Landos Biopharma SG&A Expense (Quarterly): 6.144M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 6.144M |
| December 31, 2023 | 3.463M |
| September 30, 2023 | 2.136M |
| June 30, 2023 | 1.976M |
| March 31, 2023 | 3.153M |
| December 31, 2022 | 3.099M |
| September 30, 2022 | 2.967M |
| June 30, 2022 | 4.662M |
| March 31, 2022 | 4.153M |
| Date | Value |
|---|---|
| December 31, 2021 | 6.952M |
| September 30, 2021 | 3.059M |
| June 30, 2021 | 2.596M |
| March 31, 2021 | 2.646M |
| December 31, 2020 | 1.44M |
| September 30, 2020 | 1.453M |
| June 30, 2020 | 1.365M |
| March 31, 2020 | 1.08M |
| December 31, 2019 | 0.381M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.381M
Minimum
Dec 2019
6.952M
Maximum
Dec 2021
2.929M
Average
2.806M
Median
SG&A Expense (Quarterly) Benchmarks
| AbbVie Inc | 3.315B |
| Fusion Pharmaceuticals Inc | 14.55M |
| Masimo Corp | 159.90M |
| Kinnate Biopharma Inc (DELISTED) | 5.734M |
| Invivyd Inc | 14.93M |